Adult Acute Lymphoblastic Leukemia

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

Hagop M. Kantarjian, Francis J. Giles, Lydia Wunderle et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

Anthony H. Goldstone, Susan Richards, Hillard M. Lazarus et al. · Blood · 2007 · 782 citations · Full text

Medicine, Hematology, Oncology +16

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

Anthony V. Moorman, Christine J. Harrison, Georgina Buck et al. · Blood · 2006 · 748 citations · Full text

Life Sciences, Hematology, Oncology +14

Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment

Amy de Haar-Holleman, Meyling Cheok, Monique L. den Boer et al. · New England Journal of Medicine · 2004 · 644 citations · Full text

Medicine, Oncology, Pharmacology +14